| scholarly article | Q13442814 |
| P2093 | author name string | John de Groot | |
| Shulin Li | |||
| Jason T Huse | |||
| Willem W Overwijk | |||
| Amy B Heimberger | |||
| Zoran Gatalica | |||
| David Spetzler | |||
| Tiffany R Hodges | |||
| Joanne Xiu | |||
| Shouhao Zhou | |||
| Martina Ott | |||
| Jeff Swensen | |||
| P2860 | cites work | Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 |
| Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology | Q27011884 | ||
| Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. | Q27853362 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers | Q28256331 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 | Q28265132 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 | ||
| Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment | Q33865925 | ||
| Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial | Q34391446 | ||
| Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis | Q36082471 | ||
| PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients | Q36402259 | ||
| Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial | Q36726204 | ||
| Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses | Q37059782 | ||
| Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels | Q37130135 | ||
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade | Q37173548 | ||
| MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA. | Q37215533 | ||
| MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. | Q37331928 | ||
| The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. | Q37708839 | ||
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 | ||
| Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade | Q38895750 | ||
| Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation | Q39634834 | ||
| Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies | Q41654251 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma | Q43133266 | ||
| Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type | Q45005527 | ||
| A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy | Q48582050 | ||
| Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma | Q51708790 | ||
| Mutation of the PIK3CA gene in ovarian and breast cancer | Q80945762 | ||
| Biomarkers in cancer immunotherapy | Q86521792 | ||
| P433 | issue | 8 | |
| P921 | main subject | immunotherapy | Q1427096 |
| DNA mismatch repair | Q2984243 | ||
| P304 | page(s) | 1047-1057 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy | |
| P478 | volume | 19 |
| Q64969067 | A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype. |
| Q100697790 | A risk signature of three autophagy-related genes for predicting lower grade glioma survival is associated with tumor immune microenvironment |
| Q90215360 | An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments |
| Q89855466 | Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy |
| Q58713932 | Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors |
| Q91736550 | Brain immunology and immunotherapy in brain tumours |
| Q89573873 | CAR T cells and checkpoint inhibition for the treatment of glioblastoma |
| Q57291659 | CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges |
| Q55259532 | CNS cancer immunity cycle and strategies to target this for glioblastoma. |
| Q92481361 | CTLA-4 correlates with immune and clinical characteristics of glioma |
| Q49260236 | Cancer vaccine: learning lessons from immune checkpoint inhibitors |
| Q49938152 | Checkpoint Inhibitors, Palliative Care, or Hospice |
| Q90730544 | Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma |
| Q64267591 | Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma |
| Q90690161 | Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort |
| Q92457071 | Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma |
| Q60046462 | Current Options and Future Directions in Immune Therapy for Glioblastoma |
| Q64118505 | Current State of Immunotherapy for Treatment of Glioblastoma |
| Q99565922 | Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma |
| Q49317056 | Current therapeutic approaches to diffuse grade II and III gliomas. |
| Q57486475 | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time |
| Q55257766 | Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. |
| Q91871666 | Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma |
| Q55457095 | Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. |
| Q97542745 | Efficacy of ruthenium coordination complex-based Rutherrin in a preclinical rat glioblastoma model |
| Q57822861 | Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas |
| Q89767107 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
| Q94673512 | High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma |
| Q47655313 | Hypermutation and microsatellite instability in gastrointestinal cancers |
| Q62050532 | Identifying neoantigens for use in immunotherapy |
| Q38743793 | Immune Checkpoint Inhibitors in Gliomas. |
| Q47915209 | Immunotherapies for malignant glioma. |
| Q61799969 | Immunotherapy in extensive small cell lung cancer |
| Q59359679 | Immunotherapy of Primary Brain Tumors: Facts and Hopes |
| Q92675121 | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells |
| Q92033102 | Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma |
| Q55457475 | Liquid Biopsy in Primary Brain Tumors: Looking for Stardust! |
| Q90661815 | Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome |
| Q92799371 | Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
| Q88917856 | Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design |
| Q56891439 | Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma |
| Q47120629 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? |
| Q55277238 | Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. |
| Q57176314 | Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma |
| Q90441620 | RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines |
| Q57798069 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma |
| Q60914597 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? |
| Q92735748 | Rescuing imperfect antigens for immuno-oncology |
| Q90326744 | Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models |
| Q59127261 | Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report |
| Q90417081 | T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment |
| Q61800092 | Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities |
| Q49922510 | Temozolomide-associated Hypermutation in Gliomas |
| Q90113096 | The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review |
| Q52592969 | The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
| Q64245958 | The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer |
| Q64096613 | The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival |
| Q89684724 | The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas |
| Q55162070 | The possibility of cancer immune editing in gliomas. A critical review. |
| Q57174802 | Treatment of glioblastoma in adults |
| Q39228039 | Tumor Vaccines for Malignant Gliomas |
| Q90273707 | Tumor mutational burden is associated with poor outcomes in diffuse glioma |
| Q89965816 | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| Q92452822 | Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study |
| Q64075498 | Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers |
| Q93079010 | Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment |
| Q99591984 | Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine |
Search more.